A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 38, 2014, Pages 13817-13821

  Prota, Andrea E ^a   Bargsten, Katja ^a   Diaz, J Fernando ^b   Marsh, May ^a   Cuevas, Carmen ^c   Liniger, Marc ^d   Neuhaus, Christian ^d   Andreu, Jose M ^b   Altmann, Karl Heinz ^d   Steinmetz, Michel O ^a  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c PHARMAMAR S A   (Spain)

^d ETH ZURICH   (Switzerland)

Author keywords

Drug mechanism; Microtubule targeting agents; X ray crystallography

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; MACROLIDE; MAYTANSINE; PM060184; POLYKETIDE; PYRONE DERIVATIVE; RHIZOXIN; TUBULIN; TUBULIN MODULATOR;

ANIMAL; BINDING SITE; BOVINE; BREAST NEOPLASMS; CHEMISTRY; FEMALE; HUMAN; MICROTUBULE; PHASE 1 CLINICAL TRIAL (TOPIC); X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; BREAST NEOPLASMS; CATTLE; CLINICAL TRIALS, PHASE I AS TOPIC; CRYSTALLOGRAPHY, X-RAY; FEMALE; HUMANS; MACROLIDES; MAYTANSINE; MICROTUBULES; POLYKETIDES; PYRONES; TUBULIN; TUBULIN MODULATORS;

EID: 84907270556     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1408124111     Document Type: Article

References (34)

1. Dumontet C, Jordan MA (2010) Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 9(10): 790-803.
2. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4): 253-265.
3. Canta A, Chiorazzi A, Cavaletti G (2009) Tubulin: A target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 16(11): 1315-1324.
4. Zolot RS, Basu S, Million RP (2013) Antibody-drug conjugates. Nat Rev Drug Discov 12(4): 259-260.
5. Teicher BA, Doroshow JH (2012) The promise of antibody-drug conjugates. N Engl J Med 367(19): 1847-1848.
6. Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64: 15-29.
7. Hanauske AR, et al.; The EORTC Early Clinical Trials Group (1996) Phase II clinical trials with rhizoxin in breast cancer and melanoma. Br J Cancer 73(3): 397-399.
8. Bai RL, Pettit GR, Hamel E (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265(28): 17141-17149.
9. Takahashi M, et al. (1987) Rhizoxin binding to tubulin at the maytansine-binding site. Biochim Biophys Acta 926(3): 215-223.
10. Hamel E (1992) Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55(1): 31-51.
11. Kupchan SM, et al. (1972) Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 94(4): 1354-1356.
12. Verma S, et al.; EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19): 1783-1791.
13. Martín MJ, et al. (2013) Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds. J Am Chem Soc 135(27): 10164-10171.
14. Pera B, et al. (2013) New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism. ACS Chem Biol 8(9): 2084-2094.
15. Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG (1976) Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 72(1): 47-54.
16. Batra JK, Powers LJ, Hess FD, Hamel E (1986) Derivatives of 5,6-diphenylpyridazin-3-one: Synthetic antimitotic agents which interact with plant and mammalian tubulin at a new drug-binding site. Cancer Res 46(4 Pt 2): 1889-1893.
17. Prota AE, et al. (2013) Structural basis of tubulin tyrosination by tubulin tyrosine ligase. J Cell Biol 200(3): 259-270.
18. Prota AE, et al. (2013) Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science 339(6119): 587-590.
19. Neuhaus CM, Liniger M, Stieger M, Altmann KH (2013) Total synthesis of the tubulin inhibitor WF-1360F based on macrocycle formation through ring-closing alkyne metathesis. Angew Chem Int Ed Engl 52(22): 5866-5870.
20. Kiyoto S, et al. (1986) A new antitumor complex, WF-1360, WF-1360A, B, C, D, E and F. J Antibiot (Tokyo) 39(6): 762-772.
21. Gigant B, et al. (2005) Structural basis for the regulation of tubulin by vinblastine. Nature 435(7041): 519-522.
22. Cormier A, Marchand M, Ravelli RB, Knossow M, Gigant B (2008) Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep 9(11): 1101-1106.
23. Ranaivoson FM, Gigant B, Berritt S, Joullié M, Knossow M (2012) Structural plasticity of tubulin assembly probed by vinca-domain ligands. Acta Crystallogr D Biol Crystallogr 68(Pt 8): 927-934.
24. Löwe J, Li H, Downing KH, Nogales E (2001) Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol 313(5): 1045-1057.
25. Takahashi M, Kobayashi H, Iwasaki S (1989) Rhizoxin resistant mutants with an altered beta-tubulin gene in Aspergillus nidulans. Mol Gen Genet 220(1): 53-59.
26. Lopus M, et al. (2010) Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9(10): 2689-2699.
27. Erickson HK, et al. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8): 4426-4433.
28. Kato Y, et al. (1991) Studies on macrocyclic lactone antibiotics. XIII. Anti-tubulin activity and cytotoxicity of rhizoxin derivatives: Synthesis of a photoaffinity derivative. J Antibiot (Tokyo) 44(1): 66-75.
29. Martínez-Díez M, et al. (2014) PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. Biochem Pharmacol 88(3): 291-302.
30. Ravelli RB, et al. (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428(6979): 198-202.
31. Nogales E, Whittaker M, Milligan RA, Downing KH (1999) High-resolution model of the microtubule. Cell 96(1): 79-88.
32. Fourniol FJ, et al. (2010) Template-free 13-protofilament microtubule-MAP assembly visualized at 8 A resolution. J Cell Biol 191(3): 463-470.
33. Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30(7): 631-637.
34. Andreu JM (2007) Large scale purification of brain tubulin with the modified Weisenberg procedure. Methods Mol Med 137: 17-28.